Literature DB >> 14744500

Selective targeting of cancer cells using synthetic peptides.

Mohsen Shadidi1, Mouldy Sioud.   

Abstract

To establish efficient and reliable therapeutic delivery into cancer cells, a number of delivery agents and concepts have been investigated in the recent years. Among many improvements in targeted and controlled delivery of therapeutics, cell-targeting peptides have emerged as the most valuable non-immunogenic approach to target cancer cells. Peptides can be incorporated into multicomponent gene-delivery complexes for cell-specific targeting. In contrast to larger molecules such as monoclonal antibodies, peptides have an excellent tumor penetration, which make them ideal carriers of therapeutics to the site of primary tumor and the distant metastatic sites. Here we give an update on the progress made during the last two years on the identification and potential of specific synthetic tumor targeting peptides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14744500     DOI: 10.1016/j.drup.2003.11.002

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  35 in total

1.  Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model.

Authors:  Hua Zhang; Jiro Kusunose; Azadeh Kheirolomoom; Jai W Seo; Jinyi Qi; Katherine D Watson; Heather A Lindfors; Erkki Ruoslahti; Julie L Sutcliffe; Katherine W Ferrara
Journal:  Biomaterials       Date:  2008-02-06       Impact factor: 12.479

2.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

3.  Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Authors:  Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Dayson M Friaça; Ernesto S Nakayasu; Igor C Almeida; Renato A Mortara; Jacqueline F Jacysyn; Gustavo P Amarante-Mendes; Walter Magliani; Stefania Conti; Luciano Polonelli; Luiz R Travassos
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

4.  Anti-proliferative effect on a colon adenocarcinoma cell line exerted by a membrane disrupting antimicrobial peptide KL15.

Authors:  Yu-Ching Chen; Tsung-Lin Tsai; Xin-Hong Ye; Thy-Hou Lin
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Heterobivalent ligands target cell-surface receptor combinations in vivo.

Authors:  Liping Xu; Jatinder S Josan; Josef Vagner; Michael R Caplan; Victor J Hruby; Eugene A Mash; Ronald M Lynch; David L Morse; Robert J Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

6.  Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Authors:  Karan Arora; Mackenzie Herroon; Malik H Al-Afyouni; Nicholas P Toupin; Thomas N Rohrabaugh; Lauren M Loftus; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

Review 7.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

8.  Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.

Authors:  Hong-Jun Cho; Sung-Jin Lee; Sung-Jun Park; Chang H Paik; Sang-Myung Lee; Sehoon Kim; Yoon-Sik Lee
Journal:  J Control Release       Date:  2016-06-24       Impact factor: 9.776

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

10.  Venom peptides cathelicidin and lycotoxin cause strong inhibition of Escherichia coli ATP synthase.

Authors:  Sofiya Azim; Derek McDowell; Alec Cartagena; Ricky Rodriguez; Thomas F Laughlin; Zulfiqar Ahmad
Journal:  Int J Biol Macromol       Date:  2016-02-27       Impact factor: 6.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.